

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY THE EXECUTIVE DIRECTOR AND
CHIEF EXECUTIVE OFFICER

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company in relation to the increase in shareholding in the Company by Dr. Sui Xiong CAI (“**Dr. CAI**”), an executive director and chief executive officer of the Company.

The Board was informed by Dr. CAI that he has recently purchased a total of 100,000 ordinary shares of the Company (the “**Share(s)**”) in the open market, at an average price of approximately HK\$14.6105 per Share, representing approximately 0.035% of the total issued Shares of the Company. Immediately after the purchase, Dr. CAI is interested in an aggregate of 18,540,884 Shares, representing 6.564% of the total issued share capital of the Company as at the date of this announcement.

As advised by Dr. CAI, he is fully confident about the overall development prospects and potential growth of the Group. Subject to compliance with applicable laws and regulatory requirements, Dr. CAI does not rule out that he may further increase his shareholding in the Company as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, September 3, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.